T cell responses to bluetongue virus are directed against multiple and identical CD4 + and CD8 + T cell epitopes from the VP7 core protein in mouse and sheep

Vaccine

Volumn 29, Issue 40, 2011, Pages 6848-6857

  Rojas, José Manuel ^a   Rodríguez Calvo, Teresa ^a   Peña, Lourdes ^a   Sevilla, Noemí ^a  

^a Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria Consejo Superior de Investigaciones Científicas   (Spain)

Author keywords

BTV; T cell epitopes

Indexed keywords

ALPHA INTERFERON RECEPTOR; EPITOPE; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN VP7;

ALGORITHM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLUETONGUE ORBIVIRUS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; INOCULATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; SHEEP; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; VACCINATION; VIRUS IMMUNITY; VIRUS INFECTION;

ALGORITHMS; ANIMALS; BLUETONGUE VIRUS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNITY, CELLULAR; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; PEPTIDES; PROTEIN BINDING; SHEEP; VIRAL CORE PROTEINS;

EID: 80052314033     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.061     Document Type: Article

References (40)

1. Wilson A.J., Mellor P.S. Bluetongue in Europe: past, present and future. Philos Trans R Soc Lond B Biol Sci 2009, 364(September (1530)):2669-2681.
2. Mellor P., Baylis M., Mertens P.P. Bluetongue 2009, Elsevier, Academic Press, London, UK.
3. Wilson W.C., Ma H.C., Venter E.H., van Djik A.A., Seal B.S., Mecham J.O. Phylogenetic relationships of bluetongue viruses based on gene S7. Virus Res 2000, 67(April (2)):141-151.
4. Roy P., Mertens P.P. Orbiviruses and coltiviruses: molecular biology. Encyclopaedia of virology 1999, 1062-1074. Academic Press, London, United Kindom. 2nd ed. A. Granoff, R.G. Webster (Eds.).
5. Grimes J.M., Burroughs J.N., Gouet P., Diprose J.M., Malby R., Zientara S., et al. The atomic structure of the bluetongue virus core. Nature 1998, 395(October (6701)):470-478.
6. Mertens P.P., Burroughs J.N., Anderson J. Purification and properties of virus particles, infectious subviral particles, and cores of bluetongue virus serotypes 1 and 4. Virology 1987, 157(April (2)):375-386.
7. Roy P. Bluetongue virus proteins. J Gen Virol 1992, 73(December (Pt 12)):3051-3064.
8. Mertens P.P., Pedley S., Cowley J., Burroughs J.N., Corteyn A.H., Jeggo M.H., et al. Analysis of the roles of bluetongue virus outer capsid proteins VP2 and VP5 in determination of virus serotype. Virology 1989, 170(June (2)):561-565.
9. Maan S., Maan N.S., Samuel A.R., Rao S., Attoui H., Mertens P.P. Analysis and phylogenetic comparisons of full-length VP2 genes of the 24 bluetongue virus serotypes. J Gen Virol 2007, 88(February (Pt 2)):621-630.
10. Hassan S.S., Roy P. Expression and functional characterization of bluetongue virus VP2 protein: role in cell entry. J Virol 1999, 73(December (12)):9832-9842.
11. Nason E.L., Rothagel R., Mukherjee S.K., Kar A.K., Forzan M., Prasad B.V., et al. Interactions between the inner and outer capsids of bluetongue virus. J Virol 2004, 78(August (15)):8059-8067.
12. Huismans H., Van Dijk A.A. Bluetongue virus structural components. Curr Top Microbiol Immunol 1990, 162:21-41.
13. Han Z., Harty R.N. The NS3 protein of bluetongue virus exhibits viroporin-like properties. J Biol Chem 2004, 279(October (41)):43092-43097.
14. Barratt-Boyes S.M., Rossitto P.V., Stott J.L., MacLachlan N.J. Flow cytometric analysis of in vitro bluetongue virus infection of bovine blood mononuclear cells. J Gen Virol 1992, 73(August (Pt 8)):1953-1960.
15. Hemati B., Contreras V., Urien C., Bonneau M., Takamatsu H.H., Mertens P.P., et al. Bluetongue virus targets conventional dendritic cells in skin lymph. J Virol 2009, 83(September (17)):8789-8799.
16. Takamatsu H., Jeggo M.H. Cultivation of bluetongue virus-specific ovine T cells and their cross-reactivity with different serotype viruses. Immunology 1989, 66(February (2)):258-263.
17. Jeggo M.H., Wardley R.C., Taylor W.P. Role of neutralising antibody in passive immunity to bluetongue infection. Res Vet Sci 1984, 36(January (1)):81-86.
18. Jeggo M.H., Wardley R.C., Brownlie J. A study of the role of cell-mediated immunity in bluetongue virus infection in sheep, using cellular adoptive transfer techniques. Immunology 1984, 52(July (3)):403-410.
19. Stott J.L., Osburn B.I., Barber T.L. The current status of research on an experimental inactivated bluetongue virus vaccine. Proc Annu Meet U S Anim Health Assoc 1979, (83):55-62.
20. Stott J.L., Barber T.L., Osburn B.I. Immunologic response of sheep to inactivated and virulent bluetongue virus. Am J Vet Res 1985, 46(May (5)):1043-1049.
21. Janardhana V., Andrew M.E., Lobato Z.I., Coupar B.E. The ovine cytotoxic T lymphocyte responses to bluetongue virus. Res Vet Sci 1999, 67(December (3)):213-221.
22. Andrew M., Whiteley P., Janardhana V., Lobato Z., Gould A., Coupar B. Antigen specificity of the ovine cytotoxic T lymphocyte response to bluetongue virus. Vet Immunol Immunopathol 1995, 47(August (3-4)):311-322.
23. Umeshappa C.S., Singh K.P., Pandey A.B., Singh R.P., Nanjundappa R.H. Cell-mediated immune response and cross-protective efficacy of binary ethylenimine-inactivated bluetongue virus serotype-1 vaccine in sheep. Vaccine 2010, 28(March (13)):2522-2531.
24. Takamatsu H., Burroughs J.N., Wade-Evans A.M., Mertens P.P. Bluetongue, African Horse Sickness and related Orbiviurus. Proceedings of the 2nd International Symposium 1992, 491-497. CRC Press. T.E. Walton, B.I. Osburn (Eds.).
25. Gumm I.D., Newman J.F. The preparation of purified bluetongue virus group antigen for use as a diagnostic reagent. Arch Virol 1982, 72(1-2):83-93.
26. Wade-Evans A.M., Romero C.H., Mellor P., Takamatsu H., Anderson J., Thevasagayam J., et al. Expression of the major core structural protein (VP7) of bluetongue virus, by a recombinant capripox virus, provides partial protection of sheep against a virulent heterotypic bluetongue virus challenge. Virology 1996, 220(June (1)):227-231.
27. Rammensee H.G., Bachmann J., Emmerich N.P.N., Bachor O.A., Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999, 50:213-219.
28. Singh H., Raghava G.P. ProPred1: prediction of promiscuous MHC Class-I binding sites. Bioinformatics 2003, 19(May (8)):1009-1014.
29. Nielsen M., Lundegaard C., Worning P., Lauemoller S.L., Lamberth K., Buus S., et al. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci 2003, 12(May (5)):1007-1017.
30. Nielsen M., Lund O. NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction. BMC Bioinformatics 2009, 10:296.
31. Andersen M.L., Ruhwald M., Nissen M.H., Buus S., Claesson M.H. Self-peptides with intermediate capacity to bind and stabilize MHC class I molecules may be immunogenic. Scand J Immunol 2003, 52:21-27.
32. Firat H., Garcia-Pons F., Tourdot S., Pascolo S., Scardino A., Garcia Z., et al. H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies. Eur J Immunol 1999, 29(October (10)):3112-3121.
33. Calvo-Pinilla E., Rodriguez-Calvo T., Anguita J., Sevilla N., Ortego J. Establishment of a bluetongue virus infection model in mice that are deficient in the alpha/beta interferon receptor. PLoS One 2009, 4(4):e5171.
34. Schumacher T.N., Heemels M.T., Neefjes J.J., Kast W.M., Melief C.J., Ploegh H.L. Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro. Cell 1990, 62(August (3)):563-567.
35. Gairin J.E., Mazarguil H., Hudrisier D., Oldstone M.B. Optimal lymphocytic choriomeningitis virus sequences restricted by H-2Db major histocompatibility complex class I molecules and presented to cytotoxic T lymphocytes. J Virol 1995, 69(April (4)):2297-2305.
36. Hudrisier D., Oldstone M.B., Gairin J.E. The signal sequence of lymphocytic choriomeningitis virus contains an immunodominant cytotoxic T cell epitope that is restricted by both H-2D(b) and H-2K(b) molecules. Virology 1997, 234(July (1)):62-73.
37. Wang B., Yao K., Liu G., Xie F., Zhou F., Chen Y. Computational prediction and identification of Epstein-Barr virus latent membrane protein 2A antigen-specific CD8+ T-cell epitopes. Cell Mol Immunol 2009, 6(April (2)):97-103.
38. Larsen M.V., Lelic A., Parsons R., Nielsen M., Hoof I., Lamberth K., et al. Identification of CD8+ T cell epitopes in the West Nile virus polyprotein by reverse-immunology using NetCTL. PLoS One 2010, 5(September (9)):e12697.
39. Rojas J.M., McArdle S.E., Horton R.B., Bell M., Mian S., Li G., et al. Peptide immunisation of HLA-DR-transgenic mice permits the identification of a novel HLA-DRbeta1*0101- and HLA-DRbeta1*0401-restricted epitope from p53. Cancer Immunol Immunother 2005, 54(March (3)):243-253.
40. Calvo-Pinilla E., Rodriguez-Calvo T., Sevilla N., Ortego J. Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR(-/-) mice against lethal bluetongue infection. Vaccine 2009, 28(December (2)):437-445.